Myoscience, Inc., a Redwood City, California-based medical device company, has closed a $33m Series D financing.
Backers include existing investors Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Nexus Medical Partners, Saratoga Ventures, and Valiance.
Led by President & CEO Clint Carnell, Myoscience is committed to develop its platform technology, focused cold therapy (FCT), to treat conditions involving nerves.
FCT is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions and focal cryo-treatment of tissue. It has also been cleared in the United States for use in pain management and general surgical use.
The company, which is also working to raised a second tranche of up to $12m, plans to use the proceeds to commercialize the first indication in Europe, which is a treatment to reduce “dynamic facial lines”, more commonly referred to as forehead wrinkles.